We are live on ! Find out more
BLRX

BioLineRX
BLRX

15 hedge funds and large institutions have $8.21M invested in BioLineRX in 2014 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% less funds holding

Funds holding: 18 → 15 (-3)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

51% less capital invested

Capital invested by funds: $16.7M → $8.21M (-$8.47M)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
15
Holders Change
-3
Holders Change %
-16.67%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$151K
2
SM
Senvest Management
New York
+$9.66K
3
TRCT
Tower Research Capital (TRC)
New York
+$7.52K
4
NFG
Next Financial Group
Texas
+$4.29K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$4.2M
2
SFM
Sphera Funds Management
Israel
-$728K
3
PA
Perceptive Advisors
New York
-$345K
4
OM
Opaleye Management
Massachusetts
-$286K
5
VKH
Virtu KCG Holdings
New York
-$25K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Senvest Management
New York
$2.46M +$9.66K +9 +0.3%
BI
2
BVF Inc
California
$2.31M – – –
O
3
OrbiMed
New York
$1.75M – – –
OM
4
Opaleye Management
Massachusetts
$755K -$286K -266 -25%
SFM
5
Sphera Funds Management
Israel
$298K -$728K -678 -68%
Deutsche Bank
6
Deutsche Bank
Germany
$295K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$197K +$151K +141 +193%
BCA
8
Benchmark Capital Advisors
New York
$62K – – –
NFG
9
Next Financial Group
Texas
$30K +$4.29K +4 +14%
Bank of New York Mellon
10
Bank of New York Mellon
New York
$27K – – –
Morgan Stanley
11
Morgan Stanley
New York
$16K – – –
TRCT
12
Tower Research Capital (TRC)
New York
$7K +$7.52K +7 New
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$3K -$18.3K -17 -85%
Wells Fargo
14
Wells Fargo
California
$2K – – –
U
15
UBS
Switzerland
$1K -$17.2K -16 -94%
SM
16
Sabby Management
Florida
– -$4.2M -3,369 Closed
PA
17
Perceptive Advisors
New York
– -$345K -276 Closed
VKH
18
Virtu KCG Holdings
New York
– -$25K -20 Closed
Ameriprise
19
Ameriprise
Minnesota
– -$1.07K -1 Closed

BLRX Hedge Fund Activity: Q3 2014 in Review

15 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2014, worth a combined $8.21M — down 51% from $16.7M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of BLRX and 1 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $151K. The largest seller was Sabby Management, exiting entirely with an estimated $4.2M sold.

  • 15 institutional investors held BioLineRX (BLRX) as of Q3 2014, down from 18 in Q2 2014.
  • Funds reported $8.21M of BioLineRX stock for Q3 2014, down 51% quarter-over-quarter.
  • 1 fund opened new BioLineRX positions in Q3 2014 and 4 closed out, a net change of -3 holders.
  • The largest BioLineRX buyer in Q3 2014 was Renaissance Technologies, an estimated $151K added.
  • The largest BioLineRX seller in Q3 2014 was Sabby Management, an estimated $4.2M sold.

Based on aggregated 13F filings for Q3 2014.